FULL PRESCRIBING INFORMATION: CONTENTS*

For current labeling information, please visit endstream endobj 373 0 obj <> endobj 368 0 obj <>stream q 1 0 0 1 -8.661133 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.661133 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.3389 47.6228 Tm ( )Tj 19.25 -0.005 Td (6)Tj 0.0007 Tc -0.0007 Tw -19.25 54.94 Td [(dose, titration, parallel, crossover\).

4.2 Hypersensitivity Reactions

For current labeling information, please visit endstream endobj 373 0 obj <> endobj 368 0 obj <>stream q 1 0 0 1 -8.661133 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.661133 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.3389 47.6228 Tm ( )Tj 19.25 -0.005 Td (6)Tj 0.0007 Tc -0.0007 Tw -19.25 54.94 Td [(dose, titration, parallel, crossover\). VIAGRA was adm)8.5 (i)-1.5 (nistered to m)8.5 (o)0.7 (re than 3,000 patients aged )]TJ 0 -1.165 TD [(19 to 87 years, with ED of various etiologies \(organic, psychogenic, m)8.4 (i)-1.6 (xed\) with a m)8.4 (ean )]TJ 0.0003 Tc -0.0003 Tw T* [(duration of 5 years. VIAGRA dem)8.1 (onstrated sta)]TJ 0.0012 Tc -0.0012 Tw 18.92 0 Td [(tistically signif)4.2 (i)-1 (cant im)9 (provem)9 (ent com)9 (p)1.2 (ared to )]TJ 0.0009 Tc -0.0009 Tw -18.92 -1.165 Td [(placebo in all 21 studies. The studies that established benefit dem)8.7 (onstrated im)8.7 (provem)8.7 (ents in )]TJ T* [(success rates for sexual intercourse com)8.7 (p)0.9 (ared with placebo. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The effectiveness of VIAGRA was evaluated in m)8.3 (o)0.5 (st studies using several assessm)8.3 (ent )]TJ 0.0009 Tc -0.0009 Tw T* [(instrum)8.7 (ents.

How it works for PAH

The prim)8.7 (ary m)8.7 (easure in the principal studies was a sexual function questionnaire )]TJ 0.001 Tc -0.001 Tw T* [(\(the International Index of)4 ( Erectile Function - IIEF\) adm)8.8 (i)-1.2 (nistered during a 4-week treatm)8.8 (ent-f)4 (r)-1 (ee )]TJ 0.0007 Tc -0.0007 Tw T* [(run-in period, at baseline, at follow-up visits, )-4.5 (and at the end of double-blind, placebo-controlled, )]TJ T* [(at-hom)8.4 (e treatm)8.4 (e)-0.6 (nt. Two of the questions from)]TJ 0.0008 Tc -0.0008 Tw 18.41 0 Td [( the IIEF served as prim)8.6 (ary study endpoints; )]TJ 0.001 Tc -0.001 Tw -18.41 -1.165 Td (categorical responses were elicited to questions about \(1\) the ability\ to achieve erections )Tj 0.0008 Tc -0.0008 Tw T* [(sufficient for sexual intercourse over the counter drugs containing sildenafil and \(2\) the m)8.6 (aintenance of erections after penetration. The )]TJ T* (patient addressed both questions at the final visit for the last 4 weeks\ of the study. The possible )Tj 0.001 Tc -0.001 Tw T* [(categorical responses to these questions were \(0\) no attem)8.8 (p)1 (ted intercourse, \(1\) never or alm)8.8 (o)1 (st )]TJ 0.0009 Tc -0.0009 Tw T* [(never, \(2\) a few tim)8.7 (es, \(3\) som)8.7 (etim)8.7 (es, \(4\) m)8.7 (o)0.9 (st tim)8.7 (es, and \(5\))]TJ /TT1 1 Tf 0 Tc 0 Tw 24.58 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw [(alm)8.4 (o)0.6 (st always or always. Also )]TJ -24.58 -1.165 Td [(collected as part of the IIEF was inform)8.5 (ation about other aspects of sexual function, including )]TJ 0.0008 Tc -0.0008 Tw T* [(inform)8.6 (ation on erectile function, orgasm)8.6 (, desire, satisfaction with intercourse, and overall sexual )]TJ T* (satisfaction.

Does sildenafil interact with other medicines (drug interactions)?

Sexual function data were also recorded by patients in a d\ aily diary. In addition, )Tj T* (patients were asked a global efficacy question and an optional partner q\ uestionnaire was )Tj 0.0009 Tc 0 Tw T* [(adm)8.7 (i)-1.3 (nistered. )]TJ 0 Tc T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The effect on one of the m)8.3 (a)-0.7 (jor end points, m)8.3 (a)-0.7 (intena)]TJ 0.0007 Tc -0.0007 Tw 20.72 0 Td (nce of erections after penetration, is shown in )Tj 0.0005 Tc blue sildenafil -0.0005 Tw -20.72 -1.165 Td (Figure 3, for the pooled results of 5 fixed-dose, )Tj 0.0007 Tc -0.0007 Tw 19.155 0 Td [(dose-response studies of greater than one m)8.5 (onth )]TJ -19.155 -1.165 Td (duration, showing response according to baseline function. Results with \ all doses have been )Tj T* [(pooled, but scores showed greater im)8.4 (provem)8.4 (e)-0.6 (nt at the 50 and 100 m)8.4 (g)0.6 ( doses than at 25 m)8.4 (g. The )]TJ 0.0009 Tc -0.0009 Tw T* [(pattern of responses was sim)8.7 (ilar for the other principal question, the ability to achieve an )]TJ T* (erection sufficient for intercourse. VIAGRA was adm)8.5 (i)-1.5 (nistered to m)8.5 (o)0.7 (re than 3,000 patients aged )]TJ 0 -1.165 TD [(19 to 87 years, with ED of various etiologies \(organic, psychogenic, m)8.4 (i)-1.6 (xed\) with a m)8.4 (ean )]TJ 0.0003 Tc -0.0003 Tw T* [(duration of 5 years. VIAGRA dem)8.1 (onstrated sta)]TJ 0.0012 Tc -0.0012 Tw 18.92 0 Td [(tistically signif)4.2 (i)-1 (cant im)9 (provem)9 (ent com)9 (p)1.2 (ared to )]TJ 0.0009 Tc -0.0009 Tw -18.92 -1.165 Td [(placebo in all 21 studies.

The studies that established benefit dem)8.7 (onstrated im)8.7 (provem)8.7 (ents in )]TJ T* [(success rates for sexual intercourse com)8.7 (p)0.9 (ared with placebo. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The effectiveness of VIAGRA was evaluated in m)8.3 (o)0.5 (st studies using several assessm)8.3 (ent )]TJ 0.0009 Tc -0.0009 Tw T* [(instrum)8.7 (ents. The prim)8.7 (ary m)8.7 (easure in the principal studies was a sexual function questionnaire )]TJ 0.001 Tc -0.001 Tw T* [(\(the International Index of)4 ( Erectile Function - IIEF\) adm)8.8 (i)-1.2 (nistered during a 4-week treatm)8.8 (ent-f)4 (r)-1 (ee )]TJ 0.0007 Tc -0.0007 Tw T* [(run-in period, at baseline, at follow-up visits, )-4.5 (and at the end of double-blind, placebo-controlled, )]TJ T* [(at-hom)8.4 (e treatm)8.4 (e)-0.6 (nt. Two of the questions from)]TJ 0.0008 Tc -0.0008 Tw 18.41 0 Td [( the IIEF served as prim)8.6 (ary study endpoints; )]TJ 0.001 Tc -0.001 Tw -18.41 -1.165 Td (categorical responses were elicited to questions about \(1\) the ability\ to achieve erections )Tj 0.0008 Tc -0.0008 Tw T* [(sufficient for sexual intercourse over the counter drugs containing sildenafil and \(2\) the m)8.6 (aintenance of erections after penetration. The )]TJ T* (patient addressed both questions at the final visit for the last 4 weeks\ of the study. The possible )Tj 0.001 Tc -0.001 Tw T* [(categorical responses to these questions were \(0\) no attem)8.8 (p)1 (ted intercourse, \(1\) never or alm)8.8 (o)1 (st )]TJ 0.0009 Tc -0.0009 Tw T* [(never, \(2\) a few tim)8.7 (es, \(3\) som)8.7 (etim)8.7 (es, \(4\) m)8.7 (o)0.9 (st tim)8.7 (es, and \(5\))]TJ /TT1 1 Tf 0 Tc 0 Tw 24.58 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw [(alm)8.4 (o)0.6 (st always or always.

Related images for "100"

The titration )Tj 0.0007 Tc -0.0007 Tw 19.115 0 Td [(studies, in which m)8.5 (o)0.7 (st patients received 100 m)8.5 (g, )]TJ 0.0008 Tc -0.0008 Tw -19.115 -1.165 Td [(showed sim)8.6 (ilar results. Figure 3 shows that re)]TJ 0.0006 Tc -0.0006 Tw 18.355 0 Td (gardless of the baseline levels of function, )Tj -18.355 -1.165 Td (subsequent function in patients treated with VIAGRA was better than that\ seen in patients )Tj 0.0009 Tc -0.0009 Tw T* [(treated with placebo. At the sam)8.7 (e tim)8.7 (e, on-treatm)8.7 (ent function was better in treated patients who )]TJ 0.001 Tc -0.001 Tw T* [(were less im)8.8 (paired at baseline. )]TJ 0 Tc 0 Tw T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 370 0 obj <>>>/Resources 403 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 371 0 obj <>>>/Resources 405 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 405 0 obj <> endobj 406 0 obj <> endobj 404 0 obj <>stream /This label may not be the latest approved by FDA.

What are the serious side effects of sildenafil?

For current labeling information, please visit endstream endobj 403 0 obj <> endobj 407 0 obj <> endobj 402 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 369 0 obj <> endobj 364 0 obj <>stream q 1 0 0 1 -8.859192 -1.877228 cm sildenafil citrate tablets for female 0 0 612 792 re W n 1 0 0 1 8.859192 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.1408 47.6228 Tm ( )Tj 19.25 -0.005 Td (5)Tj 0.0006 Tc -0.0006 Tw -19.25 54.94 Td [(Swan-Ganz catheterization. A total dose of 40 )1.2 (m)8.4 (g)0.6 ( sildenafil was adm)8.4 (i)-1.6 (nistered by four )]TJ 0.0005 Tc -0.0005 Tw 0 -1.165 TD (intravenous infusions. )Tj 0 Tc 0 Tw T* ( )Tj 0.0008 Tc -0.0008 Tw T* [(The results from)8.6 ( this pilot study are shown in Table 1; the m)8.6 (ean resting systolic and diastolic )]TJ T* [(blood pressures decreased by 7% and 10% com)8.6 (p)0.8 (ared to baseline in these patients. Mean resting )]TJ 0.0009 Tc -0.0009 Tw T* [(values for right atrial pressure, pulm)8.7 (onary artery pressure, pulm)8.7 (onary artery occluded pressure )]TJ 0.0007 Tc -0.0007 Tw T* (and cardiac output decreased by 28%, 28%, 20% and 7% respectively.

Sildenafil (Viagra)

Even \ though this total )Tj 0.0008 Tc -0.0008 Tw T* [(dosage produced plasm)8.6 (a sildenafil concentrations which were approxim)8.6 (ately 2 to 5 tim)8.6 (es higher )]TJ 0.0007 Tc -0.0007 Tw T* [(than the m)8.5 (ean m)8.5 (axim)8.5 (u)0.7 (m)8.5 ( plasm)8.5 (a concentrations following a single oral dose of 100 m)8.5 (g)0.7 ( in )]TJ 0.0009 Tc -0.0009 Tw T* [(healthy m)8.7 (ale volunteers, the hem)8.7 (odynam)8.7 (i)-1.3 (c response to exercise was preserved in these patients. HEMODYNAMIC DATA IN PATIENTS WITH STABLE ISCHEMIC HEART )Tj -0.0008 Tc 0.0008 Tw 4.535 -1.17 Td (DISEASE AFTER IV ADMINISTRATION OF 40 MG SILDENAFIL)Tj /TT0 1 Tf 0 Tc 0 Tw 29.825 0 Td ( )Tj -0.0001 Tc 10.98 0 0 10.98 63.1408 512.7429 Tm (Means )Tj /C2_0 1 Tf 0 Tc 2.918 0 Td <0072>Tj /TT0 1 Tf 0.0006 Tc 0.0008 Tw 0.546 0 Td ( SD )Tj 0.0003 Tc 0.0011 Tw 13.628 0.071 Td [(At rest )-9349.7 (After 4 m)7.6 (i)-0.6 (nutes of exercise )]TJ ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 525.66 0.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 525.66 478.38 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 525.66 0.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 512.16 0.48 13.5 re f Q BT 10.5639 Tw 10.98 0 0 10.98 63.1408 499.5428 Tm ( n )Tj 13.44 0 Td (Baseline )Tj 0.0008 Tc 0 Tw 0.806 -1.159 Td (\(B2\) )Tj 0.0011 Tc 1.6451 Tw 4.841 1.159 Td (n Sildenafil )Tj 0.0006 Tc 0 Tw 3.404 -1.159 Td (\(D1\) )Tj 0.0008 Tc 1.8749 Tw 4.749 1.159 Td [(n Baseline n )224.1 (Sildenafil )]TJ ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 511.68 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 512.16 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 511.68 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 486.24 0.48 25.44 re f Q BT 0.0011 Tc 0.0003 Tw 10.98 0 0 10.98 63.1408 473.6228 Tm [(PAOP \(m)8.4 (m)8.4 (H)2 (g\) )-4322.4 (8 )]TJ 0.0024 Tc 0.9826 Tw 12.377 -0.071 Td ( 8.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 5.1 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.9826 Tw 1.639 -0.071 Td ( 6.5 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 4.3 )Tj 0.0027 Tc 0 Tw 3.148 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 36.0 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 13.7 )Tj 0.0027 Tc 0 Tw 3.229 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 27.8 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 15.3 )Tj ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 485.76 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 486.24 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 485.76 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 472.26 0.48 13.5 re f Q BT 0.0011 Tc 0.0003 Tw 10.98 0 0 10.98 63.1408 459.6428 Tm [(Mean PAP \(m)8.4 (m)8.4 (H)2 (g\) )-2513.6 (8 )]TJ 0.0024 Tc 0.4798 Tw 12.377 -0.071 Td ( 16.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 4 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.639 -0.071 Td ( 12.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 3.9 )Tj 0.0027 Tc 0 Tw 3.148 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 39.4 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 12.9 )Tj 0.0027 Tc 0 Tw 3.229 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 31.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 13.2 )Tj ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 471.78 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 472.26 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 471.78 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 458.28 0.48 13.5 re f Q BT 0.0009 Tc 0.0005 Tw 10.98 0 0 10.98 63.1408 445.6628 Tm [(Mean RAP \(m)8.2 (m)8.2 (H)1.8 (g\) )-2404.3 (7 )]TJ 0.0024 Tc 0.9826 Tw 12.377 -0.071 Td ( 5.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 3.7 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.9826 Tw 1.639 -0.071 Td ( 4.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022 Also )]TJ -24.58 -1.165 Td [(collected as part of the IIEF was inform)8.5 (ation about other aspects of sexual function, including )]TJ 0.0008 Tc -0.0008 Tw T* [(inform)8.6 (ation on erectile function, orgasm)8.6 (, desire, satisfaction with intercourse, and overall sexual )]TJ T* (satisfaction. Sexual function data were also recorded by patients in a d\ aily diary.

8.6 Renal Impairment

What should I know about sildenafil before taking it?

In addition, )Tj T* (patients were asked a global efficacy question and an optional partner q\ uestionnaire was )Tj 0.0009 Tc 0 Tw T* [(adm)8.7 (i)-1.3 (nistered.

)]TJ 0 Tc T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The effect on one of the m)8.3 (a)-0.7 (jor end points, m)8.3 (a)-0.7 (intena)]TJ 0.0007 Tc -0.0007 Tw 20.72 0 Td (nce of erections after penetration, is shown in )Tj 0.0005 Tc blue sildenafil -0.0005 Tw -20.72 -1.165 Td (Figure 3, for the pooled results of 5 fixed-dose, )Tj 0.0007 Tc -0.0007 Tw 19.155 0 Td [(dose-response studies of greater than one m)8.5 (onth )]TJ -19.155 -1.165 Td (duration, showing response according to baseline function. Results with \ all doses have been )Tj T* [(pooled, but scores showed greater im)8.4 (provem)8.4 (e)-0.6 (nt at the 50 and 100 m)8.4 (g)0.6 ( doses than at 25 m)8.4 (g. The )]TJ 0.0009 Tc -0.0009 Tw T* [(pattern of responses was sim)8.7 (ilar for the other principal question, the ability to achieve an )]TJ T* (erection sufficient for intercourse. The titration )Tj 0.0007 Tc -0.0007 Tw 19.115 0 Td [(studies, in which m)8.5 (o)0.7 (st patients received 100 m)8.5 (g, )]TJ 0.0008 Tc -0.0008 Tw -19.115 -1.165 Td [(showed sim)8.6 (ilar results. Figure 3 shows that re)]TJ 0.0006 Tc -0.0006 Tw 18.355 0 Td (gardless of the baseline levels of function, )Tj -18.355 -1.165 Td (subsequent function in patients treated with VIAGRA was better than that\ seen in patients )Tj 0.0009 Tc -0.0009 Tw T* [(treated with placebo. At the sam)8.7 (e tim)8.7 (e, on-treatm)8.7 (ent function was better in treated patients who )]TJ 0.001 Tc -0.001 Tw T* [(were less im)8.8 (paired at baseline.

• Sildenafil white is sometimes called the "blue pill" in popular culture.
• It remains one of the most prescribed medications for ED worldwide.
• Some individuals purchase sildenafil white without a prescription, which can be risky.
• Derived from a scientific discovery initially aimed at heart treatment.
• Viagra was the first brand to market sildenafil for ED.
• The medication can cause side effects like dizziness and upset stomach.
• Elderly patients should be cautious due to increased risk of side effects.
• Regular medical check-ups are recommended for long-term sildenafil users.
• Lifestyle changes, such as exercise and diet, can enhance treatment results.
• The medication is typically taken on an empty stomach for quicker effect.
• Research continues into new formulations and delivery methods for sildenafil

)]TJ 0 Tc 0 Tw T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 370 0 obj <>>>/Resources 403 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 371 0 obj <>>>/Resources 405 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 405 0 obj <> endobj 406 0 obj <> endobj 404 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 403 0 obj <> endobj 407 0 obj <> endobj 402 0 obj <>stream /This label may not be the latest approved by FDA.

What is the difference between sildenafil and Viagra?

How much Teva sildenafil is too much?

Fildena Super Active

For current labeling information, please visit endstream endobj 369 0 obj <> endobj 364 0 obj <>stream q 1 0 0 1 -8.859192 -1.877228 cm sildenafil citrate tablets for female 0 0 612 792 re W n 1 0 0 1 8.859192 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.1408 47.6228 Tm ( )Tj 19.25 -0.005 Td (5)Tj 0.0006 Tc -0.0006 Tw -19.25 54.94 Td [(Swan-Ganz catheterization.

• Sildenafil white is a common name for the generic version of Viagra.
• It is used to treat erectile dysfunction in men.
• Sildenafil white is known for its rapid onset of action.
• The medication works by enhancing blood flow to the penis.
• It is typically taken about 30 to 60 minutes before sexual activity.
• Sildenafil white is available in various doses, usually 25mg, 50mg, and 100mg.
• The drug should not be used with nitrate medications to avoid dangerous interactions.
• Common side effects include headache, flushing, and nasal congestion.
• It is important to follow dosage instructions provided by a healthcare provider.
• Sildenafil white can cause low blood pressure in some users.
• Store sildenafil white in a cool, dry place, away from direct sunlight.

A total dose of 40 )1.2 (m)8.4 (g)0.6 ( sildenafil was adm)8.4 (i)-1.6 (nistered by four )]TJ 0.0005 Tc -0.0005 Tw 0 -1.165 TD (intravenous infusions. )Tj 0 Tc 0 Tw T* ( )Tj 0.0008 Tc -0.0008 Tw T* [(The results from)8.6 ( this pilot study are shown in Table 1; the m)8.6 (ean resting systolic and diastolic )]TJ T* [(blood pressures decreased by 7% and 10% com)8.6 (p)0.8 (ared to baseline in these patients. Mean resting )]TJ 0.0009 Tc -0.0009 Tw T* [(values for right atrial pressure, pulm)8.7 (onary artery pressure, pulm)8.7 (onary artery occluded pressure )]TJ 0.0007 Tc -0.0007 Tw T* (and cardiac output decreased by 28%, 28%, 20% and 7% respectively.

Even \ though this total )Tj 0.0008 Tc -0.0008 Tw T* [(dosage produced plasm)8.6 (a sildenafil concentrations which were approxim)8.6 (ately 2 to 5 tim)8.6 (es higher )]TJ 0.0007 Tc -0.0007 Tw T* [(than the m)8.5 (ean m)8.5 (axim)8.5 (u)0.7 (m)8.5 ( plasm)8.5 (a concentrations following a single oral dose of 100 m)8.5 (g)0.7 ( in )]TJ 0.0009 Tc -0.0009 Tw T* [(healthy m)8.7 (ale volunteers, the hem)8.7 (odynam)8.7 (i)-1.3 (c response to exercise was preserved in these patients. HEMODYNAMIC DATA IN PATIENTS WITH STABLE ISCHEMIC HEART )Tj -0.0008 Tc 0.0008 Tw 4.535 -1.17 Td (DISEASE AFTER IV ADMINISTRATION OF 40 MG SILDENAFIL)Tj /TT0 1 Tf 0 Tc 0 Tw 29.825 0 Td ( )Tj -0.0001 Tc 10.98 0 0 10.98 63.1408 512.7429 Tm (Means )Tj /C2_0 1 Tf 0 Tc 2.918 0 Td <0072>Tj /TT0 1 Tf 0.0006 Tc 0.0008 Tw 0.546 0 Td ( SD )Tj 0.0003 Tc 0.0011 Tw 13.628 0.071 Td [(At rest )-9349.7 (After 4 m)7.6 (i)-0.6 (nutes of exercise )]TJ ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 525.66 0.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 525.66 478.38 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 525.66 0.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 512.16 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 512.16 0.48 13.5 re f Q BT 10.5639 Tw 10.98 0 0 10.98 63.1408 499.5428 Tm ( n )Tj 13.44 0 Td (Baseline )Tj 0.0008 Tc 0 Tw 0.806 -1.159 Td (\(B2\) )Tj 0.0011 Tc 1.6451 Tw 4.841 1.159 Td (n Sildenafil )Tj 0.0006 Tc 0 Tw 3.404 -1.159 Td (\(D1\) )Tj 0.0008 Tc 1.8749 Tw 4.749 1.159 Td [(n Baseline n )224.1 (Sildenafil )]TJ ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 511.68 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 512.16 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 511.68 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 486.24 0.48 25.44 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 486.24 0.48 25.44 re f Q BT 0.0011 Tc 0.0003 Tw 10.98 0 0 10.98 63.1408 473.6228 Tm [(PAOP \(m)8.4 (m)8.4 (H)2 (g\) )-4322.4 (8 )]TJ 0.0024 Tc 0.9826 Tw 12.377 -0.071 Td ( 8.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 5.1 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.9826 Tw 1.639 -0.071 Td ( 6.5 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 4.3 )Tj 0.0027 Tc 0 Tw 3.148 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 36.0 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 13.7 )Tj 0.0027 Tc 0 Tw 3.229 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 27.8 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 15.3 )Tj ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 485.76 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 486.24 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 485.76 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 472.26 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 472.26 0.48 13.5 re f Q BT 0.0011 Tc 0.0003 Tw 10.98 0 0 10.98 63.1408 459.6428 Tm [(Mean PAP \(m)8.4 (m)8.4 (H)2 (g\) )-2513.6 (8 )]TJ 0.0024 Tc 0.4798 Tw 12.377 -0.071 Td ( 16.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 4 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.639 -0.071 Td ( 12.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 3.9 )Tj 0.0027 Tc 0 Tw 3.148 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 39.4 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 12.9 )Tj 0.0027 Tc 0 Tw 3.229 0.071 Td (8 )Tj 0.0024 Tc 0.4798 Tw 1.601 -0.071 Td ( 31.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0023 Tc -0.0009 Tw 0.546 0 Td ( 13.2 )Tj ET q 1 0 0 1 -8.859192 -1.877228 cm 66.36 471.78 317.16 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm q 1 0 0 1 383.52 472.26 cm 0 0 m 70.74 0 l 70.74 -0.48 l 0 -0.48 l f Q Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 471.78 90.48 0.48 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 66.36 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 184.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 202.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 274.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 293.94 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 364.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 383.04 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 454.26 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 473.04 458.28 0.48 13.5 re f Q q 1 0 0 1 -8.859192 -1.877228 cm 544.26 458.28 0.48 13.5 re f Q BT 0.0009 Tc 0.0005 Tw 10.98 0 0 10.98 63.1408 445.6628 Tm [(Mean RAP \(m)8.2 (m)8.2 (H)1.8 (g\) )-2404.3 (7 )]TJ 0.0024 Tc 0.9826 Tw 12.377 -0.071 Td ( 5.7 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.787 0 Td <0072>Tj /TT0 1 Tf 0.0022 Tc -0.0008 Tw 0.546 0 Td ( 3.7 )Tj 0.0027 Tc 0 Tw 3.377 0.071 Td (8 )Tj 0.0024 Tc 0.9826 Tw 1.639 -0.071 Td ( 4.1 )Tj /C2_0 1 Tf 0 Tc 0 Tw 2.82 0 Td <0072>Tj /TT0 1 Tf 0.0022